02295nas a2200445 4500000000100000008004100001260001700042653001500059653001000074653001100084653003000095653001000125653002100135653001100156653001900167653003800186653001300224653001100237653001100248653002000259653002800279653002800307653000900335653001600344653003000360653002600390653004600416653001600462100001700478700001300495700001300508700001500521700001700536245013600553856004800689300001000737490000700747520108100754022001401835 2010 d c2010 May-Jun10aAdolescent10aAdult10aBrazil10aCation Transport Proteins10aChild10aChild, Preschool10aFemale10aGene Frequency10aGenetic Predisposition to Disease10agenotype10aHumans10aInfant10aInfant, Newborn10aLeprosy, Multibacillary10aLeprosy, Paucibacillary10aMale10aMiddle Aged10apolymerase chain reaction10aPolymorphism, Genetic10aPolymorphism, Restriction Fragment Length10aYoung Adult1 aTeixeira MAG1 aSilva NL1 aRamos AL1 aHatagima A1 aMagalhães V00a[NRAMP1 gene polymorphisms in individuals with leprosy reactions attended at two reference centers in Recife, northeastern Brazil]. uhttp://www.scielo.br/pdf/rsbmt/v43n3/14.pdf a281-60 v433 a

INTRODUCTION: To investigate susceptibility to leprosy reactions, three polymorphisms of the natural resistance-associated macrophage protein (NRAMP1) gene were determined in 201 individuals who were attended at two reference centers in Recife, between 2007 and 2008. Of these, 100 were paucibacillary and 101 were multibacillary.

METHODS: The 274C/T, D543N and 1729+55del4 polymorphisms of the NRAMP1 gene were determined using the technique of restriction fragment polymorphism on DNA extracted from peripheral blood. Allelic and genotypic frequencies were estimated by direct counting.

RESULTS: The predominant genotypes were: CC (51.8%) for 274C/T; GG (86.6%) for D543N; and +-TGTG (59.9%) for 1729+55del4. The mutant genotype 274 TT predominated in negativity of the reverse reaction (p = 0.03) and in positivity of erythema nodosum leprosum (p = 0.04).

CONCLUSIONS: Our results suggest that 274 C/T polymorphism of the NRAMP1 gene may aid in determining the susceptibility to type II reactions among leprosy patients.

 a1678-9849